Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Sarah Jones

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

September 30, 2024
Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.
Read Transcript

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

They were already on the money manager’s radar.

In Nvidia’s case, the global equities team owned the stock at the launch of the fund in 2019 at around $US4 apiece. But it sold in 2023 just before the chipmaker’s big announcement on generative artificial intelligence that turned out to be a watershed movement for the company (and the sharemarket).

It was a valuation call – Nvidia was already trading at around 60 times earnings – and while the team got back in soon after in the third quarter, the sale still weighs heavily despite riding its surge since then.

“It wasn’t easy at the time,” Wright tells The Australian Financial Review of buying back Nvidia’s shares. “But I think it made it easier because we’ve got three different people questioning the decision, and you’re making a call.”

Wright manages the global equity fund with two other portfolio managers, Theo Maas and Wendy Herringer, and senior analyst Calvin Lim.

“Nvidia has still been our number one contributor since inception,” she says. “I don’t like a share price that’s gone up a lot – I grew up on a farm, so I like to get a bargain – but you have to go away and do the work and take a long-term view, and then I think that allows you to take advantage of the opportunities.”

Still, being under exposed to the Magnificent Seven US tech stocks has cost it performance. The fund has underperformed the benchmark for the past 18 months or so.

“We didn’t have enough of those mega seven stocks when they were really ramping. It’s annoying because there are some good businesses there, but they are quite correlated,” Wright concedes. “We wanted to have more diversified exposure.”

Northcape has since closed its underweight to a more neutral position and is bullish on the next stages in AI’s development.

“If you think that ChatGPT was only launched in November 2022, we are still in 1995 by internet terms so it’s super exciting because there’s just so much out there,” Wright adds.

A tantalising miss

It also owns Microsoft, Google parent Alphabet – “we still think it’s got a lot of IP in that business, it will be one of the winners” – and US software giants Salesforce and Adobe. “We’re still looking for that killer application in software for AI.”

Novo Nordisk was another tantalising close call.

Not least because Wright met with the drugmaker just before the fund launched in 2019 and had even scribbled in her notebook that “if they get this obesity thing right, this will be amazing”.

But the fund sat-out the initial explosion in demand for the weight-loss drugs known as GLP-1s after successful drug trials of Ozempic in 2023.

“Annoyingly we missed that, but again I’m not too concerned,” she says. “It’s never too late for these things. You hear about these amazing ideas, and you’ll get the opportunities, and they’ll continue to grow.”

The fund has even been buying up more Novo Nordisk shares in the pullback.

“It’s not dissimilar to AI,” she says of the Ozempic phenomenon. “The opportunity is just so, so big, it’s staggering – 45 per cent of Americans are obese.”

Novo Nordisk, she adds, is a direct play on the thematic with just 1 per cent of the potential population using the GLP-1 drugs today.

“You don’t even need to have much imagination, it could get to 8 per cent or something if the forecasts are right... I don’t want that to be the case, but you only need a fraction of that to see value in the shares.”

For all the missed opportunities in AI and Ozempic (at least at the beginning), there have been other trends where the Northcape team have been in the right place at the right time.

Like investing in America’s ailing stormwater and sewage systems and owning stocks exposed to the $US2 trillion of investment that the government has earmarked for infrastructure, green energy projects and the local semiconductor industry.

It’s what Wright refers to as America’s “industrial renaissance” with investments in the mega projects only just starting to break ground now.

So it bought US-listed Advanced Drainage Systems which makes plastic pipes for stormwater drains and septic systems.

Since Northcape bought the stock in 2023 the share price has almost doubled and has much further to run, according to Wright, as concrete pipes fast coming to the end of their life are replaced and new roads, schools and communities are built that need such plumbing.

“We see them as a direct play on that capex growth that’s happening in the US,” she adds.

Another good call has been investing in United Rentals, the largest rental equipment company in the US that first came on to its radar in 2019. Northcape bought the stock in 2020 and has watched the shares rocket more than 700 per cent from a low in the pandemic.

According to Wright, smaller companies will struggle to provide the equipment needed to build big infrastructure projects like roads and data centres, so she expects United Rentals to keep stealing market share. It already stands at 17 per cent of the market.

“It’s a great opportunity there, and the stock is trading well below the market multiple.”

Wright is confident that the fund is back on track after 18 months of catch-up. Now that it has built up exposure to the US mega caps, it is looking for companies that are flying under the radar particularly in the mid-cap part of the market.

As the US continues to cut interest rates, the sharemarket will start to broaden out so Northcape has been adding to its approved list of stocks.

Online vehicle auction services provider Copart is the latest addition – the shares have more than doubled in the last five years – but it has not started buying shares. Yet.

“They are another random company that many people won’t have heard of, but they completely dominate in that space,” Wright says.

“There are a lot of opportunities in the mid-caps because everyone has been focused on the large caps, so it is nice to look in that area,” she adds.

Wright is among the lineup at this year’s Sohn Hearts & Minds investment conference in November, which will be held in Adelaide for the first time. The Australian Financial Review is a media partner of Sohn Hearts & Minds.

This article was originally posted by The Australian Financial Review here. 

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by the Australian Financial Review, published on 30 September 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

They were already on the money manager’s radar.

In Nvidia’s case, the global equities team owned the stock at the launch of the fund in 2019 at around $US4 apiece. But it sold in 2023 just before the chipmaker’s big announcement on generative artificial intelligence that turned out to be a watershed movement for the company (and the sharemarket).

It was a valuation call – Nvidia was already trading at around 60 times earnings – and while the team got back in soon after in the third quarter, the sale still weighs heavily despite riding its surge since then.

“It wasn’t easy at the time,” Wright tells The Australian Financial Review of buying back Nvidia’s shares. “But I think it made it easier because we’ve got three different people questioning the decision, and you’re making a call.”

Wright manages the global equity fund with two other portfolio managers, Theo Maas and Wendy Herringer, and senior analyst Calvin Lim.

“Nvidia has still been our number one contributor since inception,” she says. “I don’t like a share price that’s gone up a lot – I grew up on a farm, so I like to get a bargain – but you have to go away and do the work and take a long-term view, and then I think that allows you to take advantage of the opportunities.”

Still, being under exposed to the Magnificent Seven US tech stocks has cost it performance. The fund has underperformed the benchmark for the past 18 months or so.

“We didn’t have enough of those mega seven stocks when they were really ramping. It’s annoying because there are some good businesses there, but they are quite correlated,” Wright concedes. “We wanted to have more diversified exposure.”

Northcape has since closed its underweight to a more neutral position and is bullish on the next stages in AI’s development.

“If you think that ChatGPT was only launched in November 2022, we are still in 1995 by internet terms so it’s super exciting because there’s just so much out there,” Wright adds.

A tantalising miss

It also owns Microsoft, Google parent Alphabet – “we still think it’s got a lot of IP in that business, it will be one of the winners” – and US software giants Salesforce and Adobe. “We’re still looking for that killer application in software for AI.”

Novo Nordisk was another tantalising close call.

Not least because Wright met with the drugmaker just before the fund launched in 2019 and had even scribbled in her notebook that “if they get this obesity thing right, this will be amazing”.

But the fund sat-out the initial explosion in demand for the weight-loss drugs known as GLP-1s after successful drug trials of Ozempic in 2023.

“Annoyingly we missed that, but again I’m not too concerned,” she says. “It’s never too late for these things. You hear about these amazing ideas, and you’ll get the opportunities, and they’ll continue to grow.”

The fund has even been buying up more Novo Nordisk shares in the pullback.

“It’s not dissimilar to AI,” she says of the Ozempic phenomenon. “The opportunity is just so, so big, it’s staggering – 45 per cent of Americans are obese.”

Novo Nordisk, she adds, is a direct play on the thematic with just 1 per cent of the potential population using the GLP-1 drugs today.

“You don’t even need to have much imagination, it could get to 8 per cent or something if the forecasts are right... I don’t want that to be the case, but you only need a fraction of that to see value in the shares.”

For all the missed opportunities in AI and Ozempic (at least at the beginning), there have been other trends where the Northcape team have been in the right place at the right time.

Like investing in America’s ailing stormwater and sewage systems and owning stocks exposed to the $US2 trillion of investment that the government has earmarked for infrastructure, green energy projects and the local semiconductor industry.

It’s what Wright refers to as America’s “industrial renaissance” with investments in the mega projects only just starting to break ground now.

So it bought US-listed Advanced Drainage Systems which makes plastic pipes for stormwater drains and septic systems.

Since Northcape bought the stock in 2023 the share price has almost doubled and has much further to run, according to Wright, as concrete pipes fast coming to the end of their life are replaced and new roads, schools and communities are built that need such plumbing.

“We see them as a direct play on that capex growth that’s happening in the US,” she adds.

Another good call has been investing in United Rentals, the largest rental equipment company in the US that first came on to its radar in 2019. Northcape bought the stock in 2020 and has watched the shares rocket more than 700 per cent from a low in the pandemic.

According to Wright, smaller companies will struggle to provide the equipment needed to build big infrastructure projects like roads and data centres, so she expects United Rentals to keep stealing market share. It already stands at 17 per cent of the market.

“It’s a great opportunity there, and the stock is trading well below the market multiple.”

Wright is confident that the fund is back on track after 18 months of catch-up. Now that it has built up exposure to the US mega caps, it is looking for companies that are flying under the radar particularly in the mid-cap part of the market.

As the US continues to cut interest rates, the sharemarket will start to broaden out so Northcape has been adding to its approved list of stocks.

Online vehicle auction services provider Copart is the latest addition – the shares have more than doubled in the last five years – but it has not started buying shares. Yet.

“They are another random company that many people won’t have heard of, but they completely dominate in that space,” Wright says.

“There are a lot of opportunities in the mid-caps because everyone has been focused on the large caps, so it is nice to look in that area,” she adds.

Wright is among the lineup at this year’s Sohn Hearts & Minds investment conference in November, which will be held in Adelaide for the first time. The Australian Financial Review is a media partner of Sohn Hearts & Minds.

This article was originally posted by The Australian Financial Review here. 

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by the Australian Financial Review, published on 30 September 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by Australian Financial Review, published on Sep 30, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
July 21, 2024

Investors ‘comfortable’ about a Trump presidency, despite volatility

Economists and market experts say the outcome of the US presidential election has been largely priced in by investors as softening inflation helps to buoy sharemarkets both globally and locally.

Read More
Qiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar Colman
May 28, 2024

The AI bulls are sticking to Nvidia despite 600pc share price rally

Nvidia’s quarterly earnings once again exceeded analysts’ expectations and Portfolio Manager, Qiao Ma of Munro Partners says the rise is “nowhere close to being over”.

Read More
Munro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke Meitzel
February 15, 2024

Hedge fund Munro says Nvidia, Microsoft have more to run

Kieran Moore is portfolio manager of Munro Partners Global Growth Fund. The Melbourne-based hedge fund oversees $4.3 billion in assets.

Read More
January 24, 2024

How To Master The Art Of Winning The Room

Jonathan Pease, the creative director behind the Sohn Hearts & Minds Conference and author of the book, Winning the Room, recently sat down for a chat with Mark Bouris on Straight Talk.

Read More
2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 
January 19, 2024

Best funds of 2023 stick with bitcoin, big tech bets

Some of the best performing funds of 2023 are holding firm on bitcoin and mega-cap tech stock picks that made them big money last year.

Read More
November 19, 2023

Equity Mates review the stocks pitched at the Sohn Hearts & Minds Conference

Bryce and Ren of Equity Mates attended the Sohn Hearts & Minds Conference and reviewed the stocks pitched by our new 2023 Conference Fund Managers.

Read More
Ark Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David Rowe
November 17, 2023

‘I Know It Sounds Crazy’: Cathie Wood’s Next Big Idea

Speaking from Ark’s headquarters in Florida ahead of her appearance at the Sohn Hearts & Minds Conference on Friday, Wood says she believes disinflation is now just around the corner in the US.

Read More
ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.
November 17, 2023

ARK Founder Wood Backs Bitcoin, Banking On Spot ETF Approval

Tech investment guru Cathie Wood is still a big believer in bitcoin, so it was fitting that she chose Grayscale Bitcoin Trust as her stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
IFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee Nowytarger
November 17, 2023

Hot Stocks To Ride The Next Healthcare Trends

Healthcare stocks – from sleep apnoea giant ResMed, to cancer diagnostic biotech Telix Pharmaceuticals – were recommended at the Sohn Hearts & Minds Investment Leaders Conference on Friday.

Read More
November 17, 2023

How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

Read More
November 17, 2023

The 12 Hottest Stock Tips From This Year’s Sohn Experts

It might be time to look beyond big names. That was the message from top fund managers, company founders and super funds at the Sohn Hearts & Minds.

Read More
Azora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee Nowytarger
November 17, 2023

Webster Financial ‘Avoided The Mistakes Of US Bank Failures’

The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
November 17, 2023

Why Stock Picker Cathie Wood Of ARK Can’t Stand Google

The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back.

Read More
Munro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee Nowytarger
November 17, 2023

Wise Share Price Could Rise 50pc By 2025, Says Munro Partners

Global growth fund manager Munro has about $4.3bn in funds under management across four global funds, and usually invests in companies that are poised to win from massive structural change.

Read More
Martin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke Meitzel
November 16, 2023

Hedge Fund Veteran Talks Lowest Moment In Toscafund’s 23-Year Run

Most hedge fund managers brag about their wins and shy away from their losses – Martin Hughes is not most hedge fund managers.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.